Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 8:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 1,823 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Media Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: ASP1941, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Adolescent Immunizations Among Clinic Population
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 11 Years to 21 Years
Enrollment: 223 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Smoking Status
Interventions: Control, Media Literacy; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 13 Years to 18 Years
Enrollment: 1,211 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: McKeesport, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Hypertension, Prehypertension, Overweight, Obesity, Hypertrophy, Left Ventricular
Interventions: Electronic Media Application, Standard of care education; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 13 Years to 22 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: LMNA-Related Dilated Cardiomyopathy
Interventions: NVC-001 - Low Dose, NVC-001 - Intermediate Dose, NVC-001 - High Dose; Genetic
Lead sponsor: Nuevocor Pte. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 5 more

Conditions: Diabetes
Interventions: Study Arm A, Study Arm B, Study Arm C, Study Arm D; Dietary Supplement
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Back Pain, Neck Pain
Interventions: Cannabis, Oxycodone, Placebo for Cannabis, Placebo for Oxycodone; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years and older
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Injury Prevention
Interventions: Changing narrative intervention modules; Behavioral
Lead sponsor: George Washington University; Other
Eligibility: 11 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Portal Hypertension, Cirrhosis
Interventions: HVPG, Indocyanine Green Retention test, Liver stiffness measurement, Spleen stiffness measurement; Procedure · Drug · Device
Lead sponsor: VA Connecticut Healthcare System; Federal
Eligibility: 18 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: New Haven, Connecticut • West Haven, Connecticut

Conditions: Age
Interventions: Lower Protein, Medium Protein, Higher Protein; Other
Lead sponsor: Purdue University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Effusion Joint
Interventions: Arthrocentesis; Procedure
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Psoriasis
Interventions: BI 655066, Ustekinumab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: Los Angeles, California • Port Orange, Florida • Arlington Hts, Illinois + 9 more

Conditions: Breast Neoplasms
Interventions: lapatinib, BIBW 2992, trastuzumab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cigarette Smoking
Interventions: Harm Reduction Tax - Normal Nicotine Cigarettes Available, Harm Reduction Tax - Normal Nicotine Cigarettes Not Available, Modified Risk Tobacco Product Tax - Normal Nicotine Cigarettes Available, Modified Risk Tobacco Product Tax - Normal Nicotine Cigarettes Not Available, Nicotine Content Tax - Normal Nicotine Cigarettes Available, Nicotine Content Tax - Normal Nicotine Cigarettes Not Available, Tobacco Parity Tax - Normal Nicotine Cigarettes Available, Tobacco Parity Tax - Normal Nicotine Cigarettes Not Available; Behavioral
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 21 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Buffalo, New York • Roanoke, Virginia

Conditions: Covid19
Interventions: Famotidine, N-Acetyl cysteine; Drug
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Easley, South Carolina • Greenville, South Carolina • Greer, South Carolina

Conditions: Otitis Media With Effusion
Interventions: lansoprazole, placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 2 Years to 12 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute Pulmonary Embolism
Interventions: Endobronchial ultrasound (EBUS); Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 2
States / cities: Los Angeles, California • Santa Monica, California

Conditions: Otitis Media With Effusion
Interventions: OTO-201, Sham; Drug
Lead sponsor: Otonomy, Inc.; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions: nicotine lozenge, nicotine patch; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Miami Beach, Florida • Augusta, Georgia + 7 more

Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: Placebo for AZD8965, AZD8965 low dose, AZD8965 medium dose, AZD8965 high dose; Other · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 30 more

Conditions: Gout
Interventions: ABP-671, Allopurinol, Placebo; Drug · Other
Lead sponsor: Atom Therapeutics Co., Ltd; Industry
Eligibility: 19 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 35
States / cities: Tempe, Arizona • Tuscon, Arizona • Anaheim, California + 27 more

Conditions: Acute Otitis Media
Interventions: Tympanostomy tube placement, Amoxicillin-Clavulanate and/or Ceftriaxone, Ofloxacin Otic; Device · Drug
Lead sponsor: Alejandro Hoberman; Other
Eligibility: 6 Months to 35 Months
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Pittsburgh, Pennsylvania

Conditions: Covid19, Risk Reduction, Stress, Sleep
Interventions: Hiking challenge, Activity list; Behavioral · Other
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Diabetes Mellitus
Interventions: Pioglitazone, Glimepiride; Drug
Lead sponsor: Takeda; Industry
Eligibility: 45 Years to 85 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.

Facilitating Completion of HPV Vaccination

Media Literacy to Prevent Adolescent Smoking

EMPower: Electronic Media Powering Positive Health Changes in Youth

A Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA)

Vitamins C and Vitamin E and Cardiovascular Risk

Cannabis Versus Oxycodone for Pain Relief

Changing Youth Narratives on Firearm Violence ("Run It Up") Intervention

Surrogate Markers of Portal Pressure

Dietary Protein Requirement of Elderly Men and Women

Ultrasound Guided Versus Landmark Guided Small & Medium Joint Arthrocentesis

BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab

6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab

Effects of Tax Proposals and Cigarette Availability on Tobacco Purchasing

Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19

A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion

Pilot Study to Evaluate the Role of EBUS in the Diagnosis of Acute PE in Critically Ill Patients

OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement

Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout

Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media

The Get Outside Study

Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.